证券日报网讯 1月13日，南京熊猫（600775）在互动平台回答投资者提问时表示，公司主营业务聚焦智 慧交通与平安城市、工业互联网与智能制造、绿色服务型电子制造三大领域，目前未发生任何变化。截 至目前，公司尚无与脑机接口相关的成熟产品，亦未形成相关销售收入。 ...

Core Viewpoint - The article discusses the recent fluctuations in the A-share market, highlighting the mixed sentiment among investors and the potential for continued volatility leading up to the Two Sessions in March [1][3]. Market Overview - On January 13, the three major indices in the A-share market collectively declined, with the Shanghai Composite Index down 0.64%, the Shenzhen Component down 1.37%, and the ChiNext down 1.96% [8]. - The total trading volume reached 36,991.09 billion yuan, an increase of 541.38 billion yuan from the previous day, setting a new historical record [8]. - Over 3,700 stocks in the market experienced declines, with 77 stocks hitting the daily limit up [8]. Sector Performance - The medical services sector showed strength, with several stocks, including Nuo Si Ge and Pu Rui Si, hitting the daily limit up [8]. - The AI application sector experienced volatility, with stocks like Tianlong Group and Di'an Diagnosis also reaching the daily limit up [8]. - The commercial aerospace sector faced adjustments, with several stocks dropping over 10% [8]. Investment Trends - According to CITIC, the current market sentiment is high, but there are no signs of weakening indicators yet. The short-term outlook suggests a continued rotation among themes and small-cap stocks until the Two Sessions [3]. - The article notes that the expected incremental capital for 2026 is projected at 30,378.13 billion yuan, with various sources contributing to this growth, including household deposits and institutional asset reallocation [4]. Company Highlights - Three Transform Technology has been involved in providing gas turbine transformers for the U.S. Musk xAI supercomputing data center, indicating a growing demand in the energy sector [6]. - TCL Technology expects a net profit of 4.21 billion to 4.55 billion yuan for 2025, representing a year-on-year growth of 169% to 191% [17]. - Dazhu CNC anticipates a net profit of 785 million to 885 million yuan for 2025, driven by increased demand for AI server components [17]. Regulatory and Policy Updates - The Ministry of Commerce announced the continuation of anti-dumping duties on imported solar-grade polysilicon from the U.S. and South Korea, effective January 14, 2026, for a period of five years [13]. - The article mentions a strategic partnership between EndoQuest Robotics and NVIDIA to enhance surgical robotics with high-performance computing [14]. Capital Flow Insights - The net outflow of main funds reached 117.06 billion yuan, with the electronic sector experiencing the largest outflow [20]. - The article highlights the net inflow of funds into sectors such as media, pharmaceuticals, and non-ferrous metals, while sectors like electronics and defense saw significant outflows [20].

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Market Analysis - The A-share market experienced a correction, ending a 17-day consecutive rise, with the Shanghai Composite Index closing at 4138.76 points, down 0.64% [3] - The Shenzhen Composite Index fell by 1.37% to 14169.40 points, while the ChiNext Index dropped 1.96% to 3321.89 points, indicating a broad market adjustment [3] - Despite the market correction, trading volume remained high at 3.7 trillion yuan, reflecting sustained trading activity [8] Sector Performance - A shift in market style was observed, with funds moving from high-position themes to defensive sectors, such as oil and petrochemicals, pharmaceuticals, and non-ferrous metals, which saw gains [6] - The commercial aerospace sector faced significant declines, with a drop of 6.15%, marking the largest single-day decline since the recent rally began [6] - The lithium carbonate futures surged, reaching a new high of 174,060 yuan/ton, driven by strong demand and supply constraints [12] Bond Market - The government bond futures market showed a recovery, with the 30-year contract (TL2603) rising by 0.28% to close at 111.35 yuan [12] - The central bank's net injection of 342.4 billion yuan contributed to a generally loose liquidity environment, despite short-term interest rates rising [12] - The bond market sentiment improved, indicating a potential shift towards long-term bonds as the new year begins [18] Commodity Market - The commodity market displayed significant divergence, with non-ferrous metals maintaining a leading position, while other sectors faced pressure [10] - The South China commodity index closed at 2736.38 points, down 0.24%, with lithium carbonate, silver, and tin leading the gains [10] - Geopolitical uncertainties in the Middle East have contributed to rising oil prices, with potential implications for global oil supply [13] Investment Themes - Key investment themes include AI applications, commercial aerospace, nuclear fusion, quantum technology, brain-computer interfaces, robotics, and consumer sectors, all supported by policy initiatives and technological advancements [14] - The insurance and brokerage sectors are expected to benefit from high trading volumes in the A-share market, with potential changes in trading regulations being monitored [14] - The precious metals sector is anticipated to perform well due to central bank purchases and expectations of further interest rate cuts by the Federal Reserve [14]

证券日报网讯 1月13日，首都在线在互动平台回答投资者提问时表示，脑机接口作为前沿科技领域，其 技术研发与商业化落地高度依赖底层云计算资源的强力支撑。公司深耕云计算领域多年，凭借高性能、 弹性可扩展的算力资源，可高效支撑脑机接口实验产生的海量多模态信号的实时解码分析，为合作方的 模型训练与算法优化提供强劲算力支持；同时，依托安全可靠的云存储与数据管理能力，保障实验数据 全生命周期的安全传输与高效管理。 （文章来源：证券日报） ...

Core Insights - The report highlights the emergence of new investment themes, including AIGC index, photolithography, phosphor chemical industry, vehicle networking, and brain-computer interfaces, indicating a right-side breakout in these sectors [3][4] - It identifies trends in sectors such as intelligent AI, mobile payments, aluminum, and low-altitude economy, suggesting a right-side trend formation [3][4] - The report also notes stabilization at the bottom for industries like pig farming, insurance capital stakes, yellow wine, and innovative pharmaceuticals, indicating potential recovery [3][4] - Additionally, it points out bottom reversal opportunities in sectors like innovative pharmaceuticals, methanol, and industrial software, suggesting a shift in market dynamics [3][4] Right-Side Breakout Opportunities - New indices showing right-side breakout include cloud office index, big data index, and photolithography index, with respective 5-day gains of 8%, 10%, and 12% [8] - The phosphor chemical index has shown a 4% increase over 5 days, indicating a potential investment opportunity [8] - Other indices such as vehicle networking and brain-computer interface also show promising short-term performance [8] Right-Side Trend Opportunities - The report lists indices like intelligent AI and mobile payment with 5-day gains of 11% and 5% respectively, indicating a positive trend [10] - The aluminum industry index has shown a 15% increase over 20 days, suggesting strong momentum [10] - The low-altitude economy index has also demonstrated a 22% increase over 20 days, highlighting its growth potential [10] Bottom Stabilization Opportunities - The pig farming index has stabilized with a 1% gain over 5 days, indicating potential for recovery [14] - The insurance capital stake index has shown a similar trend with a 1% increase, suggesting investor confidence [14] - Other sectors like yellow wine and innovative pharmaceuticals also show signs of stabilization, with respective gains of 1% and 12% [14] Bottom Reversal Opportunities - The methanol index has shown a 6% increase over 5 days, indicating a potential reversal in market sentiment [18] - The industrial software index has demonstrated a 13% gain, suggesting a strong recovery signal [18] - The innovative pharmaceuticals index has also shown a 12% increase, indicating a positive shift in market dynamics [18]

Group 1 - The current spring market rally in the technology sector has shown internal differentiation, with traditional themes like computing power, PCB, and CPO underperforming compared to satellite navigation, commercial aerospace, and brain-computer interfaces [1] - As of Q3 2025, the top three sectors in fund holdings are electronics (26%), electric new energy (12%), and pharmaceuticals (10%), collectively accounting for 48% of total holdings, making it challenging to sustain significant excess returns [1] - The influx of new capital has been primarily driven by substantial inflows into A500 ETF, which has spread to margin trading, small orders, and private equity, indicating a trading-oriented capital structure [1] Group 2 - Current non-consensus themes to watch include opportunities in non-ferrous metals, brain-computer interfaces, semiconductors, robotics, AI applications, and insurance [2] - The trading heat in popular sectors is not overly heated, with significant ETF inflows and high earnings growth expectations for the respective industries [3] Group 3 - TMTG plans to start construction of the world's largest commercial fusion power plant in 2026, aiming for a capacity of 50MW initially and a long-term goal of 350-500MW, with the first power generation targeted for 2031 [4] - The fusion industry is experiencing a resonance of "policy, industry, and capital," with strong policy support as fusion is included in China's 14th Five-Year Plan and recognized as a core future industry [4] - Various technological paths, including stellarators and Z-pinch, are receiving capital investment, with companies like Helical Fusion signing power purchase agreements and domestic startups completing significant financing rounds [5] Group 4 - Investment opportunities in the fusion industry are expected to concentrate on midstream equipment and upstream materials, including magnets, power supplies, and heating systems as engineering logic strengthens [6]

Core Viewpoint - The article highlights the significant decline in the performance of Kuaizi Jiao (口子窖), a prominent Chinese liquor company, indicating a broader downturn in the liquor industry, driven by market differentiation, changing consumer demand, and increased competition [1][3][10]. Financial Performance - Kuaizi Jiao's 2025 annual profit forecast is between 662 million to 828 million CNY, representing a year-on-year decrease of 50% to 60% [1]. - The company's net profit for the first three quarters of 2025 was 742 million CNY, down 43.39% year-on-year, with a significant drop of 92.55% in the third quarter alone [3][9]. - The fourth quarter is expected to yield a net profit ranging from a loss of 79.9 million CNY to a profit of 85.6 million CNY, indicating a potential year-on-year decline of approximately 75% [3]. Market Dynamics - The liquor industry is experiencing a deep adjustment period, with Kuaizi Jiao's performance serving as a clear signal of the challenges faced by the sector [7]. - The company attributes its declining performance to market differentiation, channel changes, and a drop in demand, particularly for high-end products [3][4]. - Increased competition from other brands, such as Gujing Gongjiu and Yingjia Gongjiu, has eroded Kuaizi Jiao's market share [4]. Inventory and Channel Issues - The company is facing significant inventory pressures, with a backlog of stock that has not been adequately addressed, leading to a painful de-inventory process [9][10]. - The second quarter of 2025 saw a decline in channel confidence, exacerbated by a "ban on alcohol" in May, which negatively impacted sales [7]. Valuation and Market Sentiment - Kuaizi Jiao's current market valuation has reached a dynamic price-to-earnings ratio of 24.2 times, which is considered high compared to its historical performance and even exceeds that of leading brands like Kweichow Moutai [11]. - The article suggests that the capital market is losing patience with traditional industries like liquor, favoring emerging sectors such as commercial aerospace and brain-computer interfaces [13][14]. Future Outlook - The liquor industry is expected to face further challenges in 2026, with predictions of continued declines in both volume and price, leading to a potential further drop in net profits [15][19]. - The need for liquor companies to rebuild their pricing structures and manage accumulated channel inventory may take one to two years, a timeframe that the capital market may find difficult to tolerate [16][17].

证券日报网讯 1月13日，国际医学（000516）在互动平台回答投资者提问时表示，公司旗下医疗机构依 托先进的诊疗设备、技术优势和患者资源，在脑机接口领域开展了相关课题研究，已积累一定病例样 本，进行部分数据分析、文章撰写与学术会议交流。 ...

格隆汇1月13日丨昭衍新药(603127.SH)在互动平台表示，公司非人灵长类模型主要是自用，用于非临床 安评实验相关研究，不涉及脑机接口业务。 ...